|
Oxford Glycosciences has recommended that shareholders accept a £101m takeover offer from Celltech. 14-Apr-2003 Celltech has launched a £101m hostile takeover bid for Oxford Glycosciences, trumping last month's agreed deal with Cambridge Antibody Technology. 27-Feb-2003 Cambridge Antibody Technology has offered to acquire Oxford Glycosciences for £110m, and the group's combined cash reserve of £260m will be used to license new drugs or acquire another biotechnology company. 24-Jan-2003 Oxford Glycosciences is looking into the possibility of merging with a rival biotechnology company, having failed to win US regulatory approval for its Vevesca treatment for Gaucher's disease. 25-Jun-2002 Oxford Glycosciences is to collaborate with BioInvent of Sweden to develop new therapeutic antibodies over the next three years, and will invest £3.5m in BioInvent shares. 15-Mar-2002 Oxford Glycosciences is forming a joint venture with NeoGenesis of the US to conduct research into "small molecule" drugs that can target proteins implicated in disease. 21-Jun-2001 Oxford Glycosciences and Marconi are forming a £30m joint venture called Confirmant to develop a database of human proteins, and they will also offer IT outsourcing services to pharmaceutical and biotechnology companies. 18-Jun-2001 Oxford Glycosciences and Dow AgroSciences are to take 73,000 sq ft of space at the Milton Business Park in Oxfordshire. 21-May-2001 Oxford Glycosciences is planning to expand its biotechnology business into drug development, and is seeking potential partners in order to minimise the infrastructure costs. 16-Mar-2001 Oxford Glycosciences is forming an alliance with Glaxo Wellcome to conduct research into proteins associated with specific diseases, and Glaxo will use the technology to monitor the progress of drugs through trials. 04-Dec-2000 Oxford Glycosciences is planning to raise £150m in a share offer, in order to develop new drugs, recruit 75 sales staff and fund acquisitions. 14-Nov-2000 Oxford Glycosciences is planning to create up to 40 jobs at its new drug discovery head office and factory near Abingdon. 02-Nov-2000 Oxford Glycosciences is planning to seek a secondary listing on Nasdaq, in order to help with the expansion of its biotechnology business into the US. 20-Sep-2000 Oxford Glycosciences is forming an alliance with Medarex of the US to develop new drugs using proteomics technology, and a separate alliance with Cambridge Antibody Technology to develop protein chips. 12-Sep-2000 Oxford Glycosciences is seeking new partnerships with pharmaceutical and biotechnology companies, having won a US patent to protect technology for the identification of proteins used in drug discovery. 17-May-2000 Oxford Glycosciences is to raise £33m in a share placing in order to develop new techniques for identifying proteins in DNA testing. 25-Feb-2000 Oxford Glycosciences is to collaborate with Pfizer of the US to study atherosclerosis, and has also formed a research agreement with Cellular Genomics of the US to study immunology. 16-Sep-1999 Oxford Glycosciences is to expand into a new building at Milton Park near Abingdon later this year, from where it will develop databases for drug companies. 14-May-1999 Oxford Glycosciences has been awarded a £16m five-year research contract by Pioneer Hi-Bred of the US that will involve identifying plant genes that improve the quality of seeds. 23-Sep-1998 Oxford Glycosciences is to raise £30m in a flotation, and some of the shares will go to Pzifer and Incyte Pharmaceuticals of the US. 08-Apr-1998 Oxford Glycosciences has reached agreement to conduct research into Alzheimers disease on behalf of Pfizer, and will receive up to £30m in payments including royalties on any new drugs that result. 06-Apr-1998
|